Cargando…
Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review
Behavioral and psychological symptoms represent common complications in patients with different types of dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological colle...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953267/ https://www.ncbi.nlm.nih.gov/pubmed/29785112 http://dx.doi.org/10.2147/NDT.S163842 |
_version_ | 1783323331904143360 |
---|---|
author | Masopust, Jiří Protopopová, Dita Vališ, Martin Pavelek, Zbyšek Klímová, Blanka |
author_facet | Masopust, Jiří Protopopová, Dita Vališ, Martin Pavelek, Zbyšek Klímová, Blanka |
author_sort | Masopust, Jiří |
collection | PubMed |
description | Behavioral and psychological symptoms represent common complications in patients with different types of dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological collecting, or shouting. Their appearance is related to more rapid progression of the disease, earlier institutionalization, use of physical restraints, and higher risk of mortality. Consequently, appearance of behavioral and psychological symptoms of dementia leads to higher costs of care provided and greater distress for caregivers. Clinical guidelines recommend nonpharmacological approaches as the first choice in the treatment of behavioral and psychological symptoms. Pharmacological therapy should be initiated only if the symptoms were not the result of somatic causes, did not respond to nonpharmacological interventions, or were not caused by the prior medication. Acetylcholinesterase inhibitors, memantine, antipsychotic drugs, antidepressants, mood stabilizers, and benzodiazepines are used. This review summarizes the current findings about the efficacy and safety of the treatment of the neuropsychiatric symptoms in dementias with psychopharmaceuticals. Recommendations for treatment with antipsychotics for this indication are described in detail as this drug group is prescribed most often and, at the same time, is related to the highest risk of adverse effects and increased mortality. |
format | Online Article Text |
id | pubmed-5953267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59532672018-05-21 Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review Masopust, Jiří Protopopová, Dita Vališ, Martin Pavelek, Zbyšek Klímová, Blanka Neuropsychiatr Dis Treat Review Behavioral and psychological symptoms represent common complications in patients with different types of dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological collecting, or shouting. Their appearance is related to more rapid progression of the disease, earlier institutionalization, use of physical restraints, and higher risk of mortality. Consequently, appearance of behavioral and psychological symptoms of dementia leads to higher costs of care provided and greater distress for caregivers. Clinical guidelines recommend nonpharmacological approaches as the first choice in the treatment of behavioral and psychological symptoms. Pharmacological therapy should be initiated only if the symptoms were not the result of somatic causes, did not respond to nonpharmacological interventions, or were not caused by the prior medication. Acetylcholinesterase inhibitors, memantine, antipsychotic drugs, antidepressants, mood stabilizers, and benzodiazepines are used. This review summarizes the current findings about the efficacy and safety of the treatment of the neuropsychiatric symptoms in dementias with psychopharmaceuticals. Recommendations for treatment with antipsychotics for this indication are described in detail as this drug group is prescribed most often and, at the same time, is related to the highest risk of adverse effects and increased mortality. Dove Medical Press 2018-05-09 /pmc/articles/PMC5953267/ /pubmed/29785112 http://dx.doi.org/10.2147/NDT.S163842 Text en © 2018 Masopust et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Masopust, Jiří Protopopová, Dita Vališ, Martin Pavelek, Zbyšek Klímová, Blanka Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
title | Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
title_full | Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
title_fullStr | Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
title_full_unstemmed | Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
title_short | Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
title_sort | treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953267/ https://www.ncbi.nlm.nih.gov/pubmed/29785112 http://dx.doi.org/10.2147/NDT.S163842 |
work_keys_str_mv | AT masopustjiri treatmentofbehavioralandpsychologicalsymptomsofdementiaswithpsychopharmaceuticalsareview AT protopopovadita treatmentofbehavioralandpsychologicalsymptomsofdementiaswithpsychopharmaceuticalsareview AT valismartin treatmentofbehavioralandpsychologicalsymptomsofdementiaswithpsychopharmaceuticalsareview AT pavelekzbysek treatmentofbehavioralandpsychologicalsymptomsofdementiaswithpsychopharmaceuticalsareview AT klimovablanka treatmentofbehavioralandpsychologicalsymptomsofdementiaswithpsychopharmaceuticalsareview |